Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer

Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer

Abstract HER2 overexpression/amplification (HER2+) occurs in approximately 15–20% of breast cancer (BC) and identifies a highly aggressive BC subtype. The cure rate of HER2 + BC has been significantly increased through recent clinical achievements; however, a non-negligible proportion of patients st...

Full description

Saved in:
Bibliographic Details
Main Authors: Lorenzo Castagnoli, Francesco Bonì, Martina Bigliardi, Paolo Toneguzzo, Paola A. Corsetto, Giorgia Galasso, Alma Franceschini, Paolo Cocomazzi, Viola Regondi, Cristian Capuzzoni, Angela M. Rizzo, Francesca Ligorio, Claudio Vernieri, Pierfausto Seneci, Daniela Arosio, Elda Tagliabue, Eloise Mastrangelo, Mario Milani, Serenella M. Pupa
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
Breast cancer
HER2
CD36
Fatty acid uptake
Drug resistance
Drug discovery technologies
Online Access:https://doi.org/10.1038/s41598-025-14639-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-14639-z

Similar Items